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Background: Optimal periprocedural management of anticoagulation before and after atrial fibrillation (AF) ablation is necessary to prevent 
thromboembolism while avoiding bleeding complications. However the management of anticoagulation therapy is not uniform .The safety, efficacy 
and dosing of Dabigatran as an alternative anticoagulant for AF ablation remains undetermined.
methods: : Single center Observational study included 116 consecutive patients undergoing AF ablation. There were 71 males (61.2%) and 45 
females (38.7%). 101 underwent Radiofrequency catheter ablation and 15 Cryo ablation. 50 patients received Dabigatran at 150 mg bid dose and 
66 patients were on therapeutic INR(2.0-3.0)or bridged with Lovenox. All patients receiving dabigatran therapy who underwent AF ablation on peri 
procedural Dabigatran were given the last dose 24 hours prior to the procedure and restarted 6 hours after sheath removal. In the Dabigatran group, 
14 (28%) were female and 36 (72%) male. Ages ranged between 32 and 75 years (average age 56.3 yrs). Average CHADS2 score was 1.06 with 49 
(98%) patients out of 50 having a GFR>60 ml/min.
results: Two cases of Pericardial effusion(3.03%) needing pericardiocentesis and 2 hematomas(3.03 %) occurred in the warfarin group compared 
with none in the Dabigatran group. One patient had GI bleed needing transfusion with Dabigatran. No thromboembolic complications were seen in 
either group.
conclusion: In patients undergoing AF ablation, peri procedural Dabigatran was safe and effective in preventing thromboembolic complications as 
compared with uninterrupted warfarin therapy. Further evaluation and standardization of protocols will help establish the newer anticoagulants as a 
safe, effective and convenient therapy.
